Iovance Biotherapeutics Inc
A California biotech that turns a patient's own tumor-fighting immune cells into a cancer treatment, sold as the drug Amtagvi for advanced melanoma. It started in 2007 as Genesis Biopharma, later merged with Lion Biotechnologies, and took the name Iovance in 2017. Its Amtagvi became the first cell therapy the FDA approved for a solid tumor cancer in 2024.
Bought 21.00M
Granted 40.0K · Bought 310.0K
Granted 921.9K · Bought 27.0K
Granted 152.8K · Bought 5.6K
Granted 170.0K · Bought 30.0K
Granted 285.0K
Granted 278.7K
Bought 10.0K
Granted 128.5K
Granted 50.0K · Bought 7.5K · Sold 50.0K
Bought 42.0K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Rothbaum Wayne P.Director · 5 transactions | +297.1% | 28.07Mas of Feb 2024 | — | 21.00M | — |
| McPeak Merrill ADirector · 8 transactions | — | 568.8Kas of Feb 2024 | 40.0K | 310.0K | — |
| Vogt Frederick GInterim CEO & General Counsel, Director · 49 transactions | — | 562.5K | 921.9K | 27.0K | — |
| Puri Raj K.Chief Regulatory Officer · 21 transactions | — | 248.1K | 152.8K | 5.6K | — |
| Kirby Daniel GordonChief Commercial Officer · 7 transactions | — | 146.9K | 170.0K | 30.0K | — |
| Graf Finckenstein FriedrichChief Medical Officer · 50 transactions | — | 144.1K | 285.0K | — | — |
| Bilinsky IgorChief Operating Officer · 50 transactions | — | 137.9K | 278.7K | — | — |
| Weiser MichaelDirector · 2 transactions | — | 133.3Kas of Jun 2022 | — | 10.0K | — |
| Bellemin Jean-MarcChief Financial Officer · 10 transactions | — | 65.0Kas of Jun 2025 | 128.5K | — | — |
| Maynard Ryan DDirector · 3 transactions | — | 57.5Kas of Nov 2024 | 50.0K | 7.5K | 50.0K |
| Dukes Iain D.Director · 2 transactions | +350% | 54.0Kas of Feb 2024 | — | 42.0K | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last 5 years: +21.38M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.